Monoclonal antibody therapy
My Concierge MD offers in-home IV monoclonal antibody therapy. Noted internist Dr. David Nazarian is currently accepting high-risk, immunocompromised patients with mild to moderate coronavirus symptoms who want to avoid serious illness and hospitalization. This approach is supported by the Centers for Disease Control and Prevention for the treatment of Covid-19.
What are monoclonal antibodies?
Monoclonal antibodies are proteins made by your body’s immune system. The IV infusion adds clout to your body’s natural antibodies, boosts the immune response, and tames the COVID virus. The treatment (also known as mAb) blocks the virus from entering your cells, limiting the amount of virus in the body.
The FDA authorized the treatment with monoclonal antibodies in 2020 with an Emergency Use Authorization (EUA).
The federal government and Healthcare providers still say the best defense against the severe Covid-19 is the COVID-19 vaccine.
Monoclonal antibody treatment is not recommended for women who are pregnant or breastfeeding.
Note: Monoclonal antibodies may not work with future mutations. Current additional treatment options against the omicron variant include Paxlovid, sotrovimab, Veklury, imdevimab, bebtelovimab, (remdesivir), etesevimab, casirivimab, and molnupiravir.
Evusheld is authorized for pre-exposure prophylaxis (prevention) of COVID-19 in patients aged 12 and older.
Who is eligible for monoclonal antibodies therapy?
The following is a partial list of who is eligible:
- Positive Covid-19 test.
- Have moderate Covid-19 symptoms for a week or less.
- Don’t require oxygen.
- Be over 65 or between 12-17 and meet accepted normal weight requirements.
How effective is monoclonal antibody treatment?
Prestigious medical magazine The New England Journal of Medicine posted clinical trial results that demonstrated monoclonal antibodies help avoid hospitalization rates and emergency room visits by reducing the viral load in the blood.
An independent study by the University of Pittsburgh Medical Center (UPMC) confirmed that patients who received monoclonal antibodies had a reduced risk of hospitalization.